Hebrew
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
salivary gland neoplasms/בחילה
הקישור נשמר בלוח
10 תוצאות
Minimal acute toxicity from proton beam therapy for major salivary gland cancer.
רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
Introduction: Proton beam therapy (PBT) reduces normal organ dose compared to intensity-modulated radiation therapy (IMRT) for patients with major salivary gland tumors. It is not known whether this dosimetric advantage is clinically meaningful for reducing acute toxicity.Methods: We
Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).
רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
Salivary gland cancers (SGCs) are uncommon and account for less than 5% of all head and neck cancers, but they are histologically heterogeneous. No specific therapy, including targeted agents, has consistently improved clinical outcomes in recurrent/metastatic SGC. Recent studies suggest that
Preliminary experience with chemotherapy in advanced salivary gland neoplasms.
רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
Eight patients with advanced incurable salivary gland carcinoma were treated with the combination of cyclophosphamide, doxorubicin, and cisplatin (CAP). There were three clinical complete responses and two excellent partial responses. One of the three nonresponders had symptomatic improvement
Role of concurrent chemoradiation on locally advanced unresectable adenoid cystic carcinoma.
רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies.
רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
A phase II study was performed to assess the safety and efficacy of mitoxantrone and cisplatin in locally recurrent and/or metastatic carcinomas of the salivary glands. Between May 1997 and March 2001, a total of 14 patients were entered on this trial. All of them had previously undergone radical
Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation.
רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
BACKGROUND
As proton beam radiation therapy (PBRT) may allow greater normal tissue sparing when compared with intensity-modulated radiation therapy (IMRT), we compared the dosimetry and treatment-related toxicities between patients treated to the ipsilateral head and neck with either PBRT or
Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies.
רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
BACKGROUND
Some previous studies have shown that vinorelbine (VNB) is active in recurrent salivary gland tumors.
METHODS
Between April 1993 and April 1997, 36 patients in a Phase II randomized trial received either cisplatin, 80 mg/m(2), on Day 1 plus VNB, 25 mg/m(2), on Days 1 and 8 (every 3 weeks)
A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies.
רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
OBJECTIVE
This study determined the range of tolerable doses, clinical safety, pharmacokinetics, and preliminary evidence of clinical activity following once or twice daily administration of lapatinib in patients with solid malignancies.
METHODS
Cancer patients (n = 81) received oral doses of
Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
BACKGROUND
Adenoid cystic carcinoma (ACC) is a subtype of malignant salivary gland tumors (MSGT), in which 90% of cases express cKIT. Dasatinib is a potent and selective inhibitor of five oncogenic protein tyrosine kinases (PTKs)/kinase families including cKIT. We conducted a phase II study to
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
HER2-targeted therapies are approved only for HER2-positive breast and gastric cancers. We assessed the safety/tolerability and activity of the novel HER2-targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd) in 60 patients with pretreated, HER2-expressing (IHC ≥ 1+),
המאגר השלם ביותר של צמחי מרפא המגובה על ידי המדע
- עובד ב 55 שפות
- מרפא צמחי מרפא מגובה על ידי מדע
- זיהוי עשבי תיבול על ידי דימוי
- מפת GPS אינטראקטיבית - תייגו עשבי תיבול במיקום (בקרוב)
- קרא פרסומים מדעיים הקשורים לחיפוש שלך
- חפש עשבי מרפא על פי השפעותיהם
- ארגן את תחומי העניין שלך והתעדכן במחקר החדשות, הניסויים הקליניים והפטנטים
הקלד סימפטום או מחלה וקרא על צמחי מרפא שעשויים לעזור, הקלד עשב וראה מחלות ותסמינים שהוא משמש נגד.
* כל המידע מבוסס על מחקר מדעי שפורסם
